Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).

Kasteleijn-Nolst Trenite DGA, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA.

Neurology. 2019 Aug 6;93(6):e559-e567. doi: 10.1212/WNL.0000000000007894. Epub 2019 Jul 10.

PMID:
31292226
2.

Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants.

French JA, Wechsler R, Gelfand MA, Pollard JR, Vazquez B, Friedman D, Gong LH, Kamemoto E, Isojarvi J, Cassella JV.

Epilepsia. 2019 Aug;60(8):1602-1609. doi: 10.1111/epi.16279. Epub 2019 Jul 3.

PMID:
31268555
3.

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation.

Middleton FK, Pollard JR, Curtin NJ.

Cancers (Basel). 2018 Aug 20;10(8). pii: E275. doi: 10.3390/cancers10080275.

4.

New 4-Amino-1,2,3-Triazole Inhibitors of Indoleamine 2,3-Dioxygenase Form a Long-Lived Complex with the Enzyme and Display Exquisite Cellular Potency.

Alexandre JAC, Swan MK, Latchem MJ, Boyall D, Pollard JR, Hughes SW, Westcott J.

Chembiochem. 2018 Mar 16;19(6):552-561. doi: 10.1002/cbic.201700560. Epub 2018 Jan 31.

PMID:
29240291
5.

Detection of generalized tonic-clonic seizures using surface electromyographic monitoring.

Halford JJ, Sperling MR, Nair DR, Dlugos DJ, Tatum WO, Harvey J, French JA, Pollard JR, Faught E, Noe KH, Henry TR, Jetter GM, Lie OV, Morgan LC, Girouard MR, Cardenas DP, Whitmire LE, Cavazos JE.

Epilepsia. 2017 Nov;58(11):1861-1869. doi: 10.1111/epi.13897. Epub 2017 Oct 5.

6.

Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.

Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ Jr, Jiang W, Jiang X, Switzer RD, Privitera MD.

JAMA Neurol. 2017 Aug 1;74(8):919-926. doi: 10.1001/jamaneurol.2017.0497.

7.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.

Sanjiv K, Hagenkort A, Calderón-Montaño JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV, Schultz N, Scobie M, Charlton PA, Pollard JR, Berglund UW, Altun M, Helleday T.

Cell Rep. 2016 Dec 20;17(12):3407-3416. doi: 10.1016/j.celrep.2016.12.031. No abstract available.

8.

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ.

Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.

9.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

10.

Attitudes Toward Epilepsy Genetics Testing Among Adult and Pediatric Epileptologists-Results of a Q-PULSE Survey.

Ferraro L, Pollard JR, Helbig I.

Epilepsy Curr. 2016 Jan-Feb;16(1):46-7. doi: 10.5698/1535-7597-16.1.46. No abstract available.

11.

Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.

Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ Jr, Jiang W, Jiang X, Berg M.

Lancet Neurol. 2016 Apr;15(4):365-72. doi: 10.1016/S1474-4422(16)00014-4. Epub 2016 Feb 12.

PMID:
26875743
12.

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.

Sanjiv K, Hagenkort A, Calderón-Montaño JM, Koolmeister T, Reaper PM, Mortusewicz O, Jacques SA, Kuiper RV, Schultz N, Scobie M, Charlton PA, Pollard JR, Berglund UW, Altun M, Helleday T.

Cell Rep. 2016 Jan 12;14(2):298-309. doi: 10.1016/j.celrep.2015.12.032. Epub 2015 Dec 31. Erratum in: Cell Rep. 2016 Dec 20;17 (12 ):3407-3416.

13.

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ.

Oncotarget. 2015 Oct 20;6(32):32396-409. doi: 10.18632/oncotarget.6136.

14.

Glutamate imaging (GluCEST) lateralizes epileptic foci in nonlesional temporal lobe epilepsy.

Davis KA, Nanga RP, Das S, Chen SH, Hadar PN, Pollard JR, Lucas TH, Shinohara RT, Litt B, Hariharan H, Elliott MA, Detre JA, Reddy R.

Sci Transl Med. 2015 Oct 14;7(309):309ra161. doi: 10.1126/scitranslmed.aaa7095.

15.

Lateral Transorbital Endoscopic Access to the Hippocampus, Amygdala, and Entorhinal Cortex: Initial Clinical Experience.

Chen HI, Bohman LE, Emery L, Martinez-Lage M, Richardson AG, Davis KA, Pollard JR, Litt B, Gausas RE, Lucas TH.

ORL J Otorhinolaryngol Relat Spec. 2015;77(6):321-32. doi: 10.1159/000438762. Epub 2015 Sep 30.

16.

Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy.

Salanova V, Witt T, Worth R, Henry TR, Gross RE, Nazzaro JM, Labar D, Sperling MR, Sharan A, Sandok E, Handforth A, Stern JM, Chung S, Henderson JM, French J, Baltuch G, Rosenfeld WE, Garcia P, Barbaro NM, Fountain NB, Elias WJ, Goodman RR, Pollard JR, Tröster AI, Irwin CP, Lambrecht K, Graves N, Fisher R; SANTE Study Group.

Neurology. 2015 Mar 10;84(10):1017-25. doi: 10.1212/WNL.0000000000001334. Epub 2015 Feb 6.

17.

Development of pharmacodynamic biomarkers for ATR inhibitors.

Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ.

Mol Oncol. 2015 Feb;9(2):463-72. doi: 10.1016/j.molonc.2014.09.012. Epub 2014 Oct 13.

18.

ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y.

Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30.

19.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.

Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR.

Oncotarget. 2014 Jul 30;5(14):5674-85.

20.

Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.

Swan MK, Legris V, Tanner A, Reaper PM, Vial S, Bordas R, Pollard JR, Charlton PA, Golec JM, Bertrand JA.

Acta Crystallogr D Biol Crystallogr. 2014 May;70(Pt 5):1465-75. doi: 10.1107/S139900471400501X. Epub 2014 Apr 30.

PMID:
24816114
21.

Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression.

Hamilton KT, Anderson CT, Dahodwala N, Lawler K, Hesdorffer D, French J, Pollard JR.

Seizure. 2014 Mar;23(3):196-200. doi: 10.1016/j.seizure.2013.11.012. Epub 2013 Nov 23.

22.

Epilepsy surgery: factors that affect patient decision-making in choosing or deferring a procedure.

Anderson CT, Noble E, Mani R, Lawler K, Pollard JR.

Epilepsy Res Treat. 2013;2013:309284. doi: 10.1155/2013/309284. Epub 2013 Sep 16.

23.

Natalizumab-induced progressive multifocal leukoencephalopathy.

Thaker AA, Schmitt SE, Pollard JR, Dubroff JG.

Clin Nucl Med. 2014 Jul;39(7):e365-6. doi: 10.1097/RLU.0000000000000238.

PMID:
24152618
24.

The diagnosis and treatment of attention deficit hyperactivity disorder in patients with epilepsy.

Brown MG, Becker DA, Pollard JR, Anderson CT.

Curr Neurol Neurosci Rep. 2013 Jun;13(6):351. doi: 10.1007/s11910-013-0351-6. Review.

PMID:
23636930
25.

Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials.

Hesdorffer DC, French JA, Posner K, DiVentura B, Pollard JR, Sperling MR, Harden CL, Krauss GL, Kanner AM.

Epilepsia. 2013 May;54(5):879-87. doi: 10.1111/epi.12128. Epub 2013 Feb 28.

26.

Kinetic and mechanistic characterisation of Choline Kinase-α.

Hudson CS, Knegtel RM, Brown K, Charlton PA, Pollard JR.

Biochim Biophys Acta. 2013 Jun;1834(6):1107-16. doi: 10.1016/j.bbapap.2013.02.008. Epub 2013 Feb 13.

PMID:
23416529
27.

The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy.

Pollard JR, Eidelman O, Mueller GP, Dalgard CL, Crino PB, Anderson CT, Brand EJ, Burakgazi E, Ivaturi SK, Pollard HB.

Front Neurol. 2013 Jan 3;3:181. doi: 10.3389/fneur.2012.00181. eCollection 2012.

28.

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, Vallis KA, Hammond EM, Olcina MM, Gillies McKenna W, Muschel RJ, Brunner TB.

Cell Death Dis. 2012 Dec 6;3:e441. doi: 10.1038/cddis.2012.181.

29.

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB.

Cancer Biol Ther. 2012 Sep;13(11):1072-81. doi: 10.4161/cbt.21093. Epub 2012 Jul 24.

30.

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.

Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, McKenna WG, Hammond EM.

Br J Cancer. 2012 Jul 10;107(2):291-9. doi: 10.1038/bjc.2012.265. Epub 2012 Jun 19.

31.

Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures.

Schelleman H, Pollard JR, Newcomb C, Markowitz CE, Bilker WB, Leonard MB, Hennessy S.

Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):619-25. doi: 10.1002/pds.2141.

32.

Rescue therapies for seizures.

Poukas VS, Pollard JR, Anderson CT.

Curr Neurol Neurosci Rep. 2011 Aug;11(4):418-22. doi: 10.1007/s11910-011-0207-x. Review.

PMID:
21509498
33.

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR.

Nat Chem Biol. 2011 Apr 13;7(7):428-30. doi: 10.1038/nchembio.573.

PMID:
21490603
34.

Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.

Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM, Rutherford AP, Wang PS, Young SC, Pollard JR.

J Med Chem. 2011 Apr 14;54(7):2320-30. doi: 10.1021/jm101488z. Epub 2011 Mar 17.

PMID:
21413798
35.

Facial tic associated with lamotrigine in adults.

Musiek ES, Anderson CT, Dahodwala NA, Pollard JR.

Mov Disord. 2010 Jul 30;25(10):1512-3. doi: 10.1002/mds.23120. No abstract available.

PMID:
20629145
36.

Antiepileptic drugs and other medications: what interactions may arise?

Mani R, Pollard JR.

Curr Treat Options Neurol. 2009 Jul;11(4):253-61.

PMID:
19523351
37.

Discovery and development of aurora kinase inhibitors as anticancer agents.

Pollard JR, Mortimore M.

J Med Chem. 2009 May 14;52(9):2629-51. doi: 10.1021/jm8012129. Review. No abstract available.

PMID:
19320489
38.

Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.

Pollard JR.

Curr Opin Investig Drugs. 2008 Jan;9(1):101-7. Review.

PMID:
18183537
39.

Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy.

Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW; American Academy of Neurology.

Neurology. 2007 Apr 17;68(16):1249-50. No abstract available.

PMID:
17438213
40.

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Cheetham GM, Charlton PA, Golec JM, Pollard JR.

Cancer Lett. 2007 Jun 28;251(2):323-9. Epub 2007 Jan 19.

PMID:
17240048
41.

Antiepileptic drugs in development.

Pollard JR, French J.

Lancet Neurol. 2006 Dec;5(12):1064-7. Review.

PMID:
17110287
42.

Racial differences in the prevalence of cardiac sources of embolism in subjects with unexplained stroke or transient ischemic attack evaluated by transesophageal echocardiography.

Kizer JR, Silvestry FE, Kimmel SE, Kasner SE, Wiegers SE, Erwin MB, Schwalm SA, Viswanathan MN, Pollard JR, Keane MG, Sutton MG.

Am J Cardiol. 2002 Aug 15;90(4):395-400.

PMID:
12161229
43.

Vertebrobasilar thrombolysis with intravenous tirofiban: case report.

Liebeskind DS, Pollard JR, Schwartz ED, Cucchiara BL, McGarvey ML, Hurst RW.

J Thromb Thrombolysis. 2002 Apr;13(2):81-4.

PMID:
12101384
45.

Mechanism of 3-methylaspartase probed using deuterium and solvent isotope effects and active-site directed reagents: identification of an essential cysteine residue.

Pollard JR, Richardson S, Akhtar M, Lasry P, Neal T, Botting NP, Gani D.

Bioorg Med Chem. 1999 May;7(5):949-75.

PMID:
10400348
46.
48.
49.

Calcium channel and membrane fusion activity of synexin and other members of the Annexin gene family.

Pollard HB, Guy HR, Arispe N, de la Fuente M, Lee G, Rojas EM, Pollard JR, Srivastava M, Zhang-Keck ZY, Merezhinskaya N, et al.

Biophys J. 1992 Apr;62(1):15-8. No abstract available.

Supplemental Content

Loading ...
Support Center